Abstract 240P
Background
This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).
Methods
We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.
Results
The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P
Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients
Parameters | No. | Mean ± SEM | Median | p | |
Agea | |||||
≤ 54 | 73 | 147.47 ± 7.77 | 160 | 0.132 | |
> 54 | 49 | 163.83 ± 8.86 | 165 | ||
Gendera | |||||
Male | 107 | 152.59 ± 6.45 | 160 | 0.561 | |
Female | 15 | 164.33 ± 13.21 | 160 | ||
Tumor siteb | |||||
Buccal | 77 | 152.08 ± 7.29 | 160 | 0.700 | |
Retromolar | 24 | 148.96 ± 13.50 | 165 | ||
Tongue | 7 | 170.36 ± 25.33 | 170 | ||
Others | 14 | 165.36 ± 19.25 | 171 | ||
Histological gradeb | |||||
Well | 45 | 149.00 ± 8.18 | 165 | 0.720 | |
Moderate | 71 | 156.13 ± 8.35 | 160 | ||
Poor | 6 | 167.08 ± 30.81 | 183 | ||
Stagea | |||||
I–II | 66 | 133.60 ± 7.41 | 153 | <0.001* | |
III–IV | 56 | 178.13 ± 8.34 | 184 | ||
Tumor statusa | |||||
T1–2 | 78 | 139.20 ± 7.18 | 160 | <0.001* | |
T3–4 | 44 | 180.34 ± 8.98 | 186 | ||
Nodal metastasisa | |||||
Absent | 91 | 145.36 ± 6.39 | 160 | 0.011* | |
Present | 31 | 179.52 ± 12.64 | 180 | ||
Distant metastasisa | |||||
Absent | 107 | 148.69 ± 6.36 | 160 | 0.010* | |
Present | 15 | 192.17 ± 11.12 | 188 |
ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05
Conclusions
Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03